To appraise the clinical and cost effectiveness of abemaciclib within its marketing authorisation for treating hormone-receptor positive, HER2-negative breast cancer.
 
Status In progress
Process STA pre-2018
ID number 1227

Provisional Schedule

Expected publication 20 February 2019

Project Team

Project lead Thomas Feist

Email enquiries

Consultees

Companies sponsors Eli Lilly (abemaciclib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Breast Cancer Care
  Breast Cancer Now
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Breast Cancer Group

Commentators

Comparator companies Novartis Pharmaceuticals (ribociclib)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
18 September 2018 Committee meeting: 1
16 April 2018 Invitation to participate
19 October 2017 - 16 November 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
23 October 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance